Asia-Pacific Digital Respiratory Device Market Research Report: Forecast (2023-2028)
By Device Type (Therapeutic Devices (CPAP Devices, BI-PAP Devices, Humidifiers, Nebulizers, Ventilators, Inhalers, Oxygen Concentrates, Resuscitators), Diagnostics Monitoring Devic...es (Spirometers, Pulse Oximeters), Consumables and Accessories, Respiratory Therapy Wearable Medical Device (Watch and Wristband), Disposables (Nasal Cannulas, Filters, Breathing Circuits)), By End-User (Homecare, Hospitals and Clinics, Ambulatory Care Centers), By Application (Chronic Obstructive Pulmonary Disease, Sleep Apnea, Asthma, Infectious Disease), By Country (China, India, Japan, Australia, New Zealand, South Korea, Rest of Asia-Pacific), By Company (Philips, 3M Healthcare, Astra Zenca Plc., Novartis AG, GE Healthcare, Masimo Corporation, Cipla Ltd., Resmed Ltd., Teva Pharmaceuticals Industries Ltd., Acorda Therapeutics) Read more
- Healthcare
- Jan 2023
- 232
- PDF, Excel, PPT
Market Insights & Analysis: Asia-Pacific Digital Respiratory Device Market (2023-28)
The Asia-Pacific Digital Respiratory Device Market is projected to grow at a CAGR of around 36.2% during the forecast period, i.e., 2023-28. Most of the market expansion attributes to the mounting instances of respiratory diseases, including asthma, chronic obstructive pulmonary disease, and sleep apnea resulting in the frequent adoption of the digital technology-enabled medical device. Besides, the region’s widespread presence of other respiratory diseases, such as chronic bronchitis, emphysema, and wheezing, has swiftly augmented the demand for digital respiratory devices. For instance, per the research study titled” Global, regional, and national prevalence of asthma in 2019: a systematic analysis and modeling study”, South East Asia Region had the most significant global cases of current wheezing, with 200.57million in 2019, The age group that contributed the most was 30-34 years in West Pacific region. The countries with the most cases of current wheezing globally were China and India.
However, by means of new technological advancements in emerging economies coupled with bolstering public awareness and increased healthcare expenditure, several governments seek to mitigate respiratory ailments while improving medical facilities in their respective countries. Given the aftermath of Covid-19, China is pacing up with the inclusion of Artificial intelligence in the medicine and healthcare ecosystem. The goal is to optimize resource allocation, enhance service efficiency, and bring innovation in service and management modes.
Report Coverage | Details |
---|---|
Study Period | Historical Data: 2018-21 |
Base Year: 2022 | |
Forecast Period: 2023-28 | |
CAGR (2023-2028) | 36.2% |
Country Covered | China, India, Japan, Australia, New Zealand, South Korea, Rest of Asia-Pacific |
Key Companies Profiled | Philips, 3M Healthcare, Astra Zenca Plc., Novartis AG, GE Healthcare, Masimo Corporation, Cipla Ltd., Resmed Ltd., Teva Pharmaceuticals Industries Ltd., Acorda Therapeutics |
Unit Denominations | USD Million/Billion |
Moreover, new regulatory opportunities and difficulties arise as machine learning, and artificial intelligence (AI) become more frequent in digital health products and solutions. Thus, numerous regulatory agencies are actively developing regulatory frameworks that handle products utilizing AI/ML, such as Singapore’s HSA and Japan’s MHLW/PMDA. Furthermore, the rapid increase in the population of seniors and obese people will also likely present chances for the market for respiratory care devices to expand in the years to come. Nonetheless, the demand for respiratory care equipment may face additional challenges due to the numerous adverse effects on infants’ respiratory systems in the coming years.
Asia-Pacific Digital Respiratory Device Market Key Driver:
Increasing Prevalence of Chronic Respiratory Diseases Across APAC - COVID-19 came as a shock to the economies in the APAC region as the healthcare infrastructure was not comparable to the global benchmarks. This outbreak ultimately resulted in an increased number of patients suffering from respiratory ailments. China has the most significant number of chronic obstructive pulmonary disease incidences due to the rising aging population. As of Jan 2020, around 41.3% population in China were aged over 60 years of age, says United Nations (UN). Owing to alarming levels of air pollution, exposure to chemicals, an aging population, and rising smoking habit among inhabitants, the rate of frequency of diseases such as chronic pulmonary diseases (COPD) and asthma is growing among the people in the region. Such increasing prevalence of diseases would positively influence the supplies of respiratory devices in the forecast period.
Asia-Pacific Digital Respiratory Device Market Possible Restraint:
Concerns Related to The Precision and Reliability of Such Devices - Although the benefits of such smart devices are immense, there are some restrictions that may impede industry growth in the years to come. The prominent one would be the concerns related to the precision and dependability of the device. Also, these devices' availability and high cost hinder market expansion. Besides, given the multiple adverse impacts on newborns' respiratory systems in the coming years, the demand for respiratory care equipment may encounter new difficulties.
Asia-Pacific Digital Respiratory Device Market Growth Opportunity:
Favorable Regulatory Standards for Digital Interventions and Strategies in The Healthcare Ecosystem - In order to handle the large amount of data generated during diagnosis and treatment procedure paired with health status, efficient regulations by the government have been realizing in the past few years. The APAC region's regulatory review procedures are expected to be more consistent and predictable because of the convergence of digital health regulations, which will elevate the delivery of new, safe, and effective digital health solutions to patients and medical professionals. Furthermore, the establishment of regulatory pathways designed specifically to meet the requirements of digitalized medical products would encourage innovation, which will be advantageous to both developers and patients.
Asia-Pacific Digital Respiratory Device Market Key Trend:
The Outbreak of Covid-19 Prompting the Utmost Utilization of Digital Respiratory Devices - The sudden breakout of the pandemic in China and its spillover to other Asia-Pacific countries has increased the demand for Digital Respiratory Medical Devices exponentially. As such, the rise in the death toll and the number of infected individuals has pushed governments and private healthcare players toward adopting more sophisticated respiratory medical devices to detect, prevent and monitor such viral pandemics. Therefore, the demand is expected to proliferate in the forthcoming years as precautionary healthcare spending in various countries is likely to snowball considerably.
Asia-Pacific Digital Respiratory Device Market (2023-28): Segmentation Analysis
The Asia-Pacific Digital Respiratory Device Market study of MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2023–2028 at the global, regional, and national levels. Based on the Indication, and End-User the market has been further classified as:
Based on Indication,
- Astonary Disease
- Sleep Apnea
- Infectiou
- hma
- Chronic Obstructive Pulm
- s Disease
Among all other indications, Asthma is the most prominent across APAC, thus instigating the demand for related treatment methods in the forecast period. Concomitant allergic diseases, personal history of allergy, and cesarean birth are the prominent risk factors for developing asthma across the continent. Even with the presence of novel therapies, healthcare professionals face continuous blocks in managing respiratory diseases here. As a result, Smart inhalers are gaining traction as they have the potential to address those challenges. These inhalers are equipped with advanced features that aid the connection with mobile apps, enabling the supervision of medication schedules and subsequent doses. Besides, these devices can deliver dosage reminders, track adherence, correctly record the time, date, and location of each dose administered, and enable access to readily shareable data via Bluetooth. Furthermore, many smart devices either have sensors built into the inhaler's body or have external sensors that can be added to conventional inhalers. Backed by these aspects, the Industry for digital respiratory devices will likely gain momentum in the coming years.
Based on End-User,
- Homecare
- Hospitals and Clinics
- Ambulatory Care Centers
All things considered, Hospitals & Clinics acquired a sizeable portion of the Asia-Pacific Digital Respiratory Device Market and are projected to continue to lead in the same direction over the coming years. This growth ascribes to a rapid increase in the elderly population, which has subsequently elevated the demand for emergency and long-term hospitalizations. Consequently, increasing demand for smart respiratory machines such as BI-PAP Devices, smart inhalers, oxygen concentrates, and diagnostics monitoring devices, including spirometers and pulse oximeters. On the other hand, the swift surge in the number of premature or newborn infants with underdeveloped lungs or showing respiratory difficulties is resulting in high childhood asthma, thus, prompting medical facilities like hospitals & clinics to stock such devices for timely and proper treatment. As a result, the hospitals and clinics indicate lucrative prospects for the sector's top players, propelling the overall market trajectory through 2028.
Asia-Pacific Digital Respiratory Device Market Regional Projection
Geographically, the Asia-Pacific Digital Respiratory Device Market expands across:
- China
- India
- Japan
- Australia
- New Zealand
- South Korea
- Rest of Asia-Pacific
Country-wise, China garnered the lion’s share of the Digital Respiratory Device Market across Asia Pacific in the historical period. The outbreak of Covid -19 and the ever-increasing aging population have been the prominent factors backing the steady adoption of such devices here. It also owes to the growing prevalence of asthma, which has been an economic and social burden for children and guardians for the past three decades. As such, China announced its first health initiative, Healthy China 2030, which seeks to improve the national health system. Such initiatives would further propel the demand for smart and effective medical devices in the long run. Moreover, Medical informatics research in China has AI as a competing arena focusing on diagnostic deep-learning algorithms for medical imaging.
Similarly, according to the Journal of Global Health, ten countries alone accounted for more than half of the global cases of asthma in 2019, with India at the top, followed by China. Among India’s 1.31 billion people, about 6% of children and 2% of adults have asthma. Due to rapid urbanization and continuously increasing population awareness, the usage and advancement of digital medical devices has grown over the years. For instance, In July 2022, OMRON Healthcare India expanded its Oxygen therapy portfolio by adding an Oxygen concentrator. On the other hand, Australia acquired the leading position among pacific countries in the market, with COPD being the 5th major cause of death across the country. With one-fifth of the population already demonstrating asthma-COPD overlap syndromes (ACOS), Australia emerges as an opportunistic area for the stakeholders.
Regulatory Landscape in the Asia-Pacific Digital Respiratory Device Market
Japan
- The "SAKIGAKE" procedure was introduced by MHLW and PMDA, and it permits significantly faster approval paths for goods deemed as breakthrough technologies that solve important unmet medical requirements.
Australia
- While Singapore's HSA and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) continue to categorize Software as a medical device, SaMD using conventional medical device classification systems, the Australia’s Therapeutic Goods Administration (TGA) has developed classification standards, particularly for SaMD.
- SaMD classification-related regulatory adjustments were made by TGA on December 12, 2020 (in effect from February 25, 2021). The software classification requirements outlined in the Medical Device Regulation of the European Union are substantially consistent with these SaMD classification rules (EU Regulation 2017/745.)
- TGA increasingly relies on information from overseas regulators to assist Australian regulatory decisions. It continues to foster the creation of mutual dependence frameworks that lighten the regulatory burden on producers.
- The International Medical Devices Regulators Forum (IMDRF), the International Organization for Standardization, and the ACCESS Consortium of regulators from Australia, Canada, Singapore, the United Kingdom, and Switzerland are among the international initiatives through which TGA is also actively involved in work sharing, information sharing, and regulatory convergence activities (ISO)
Asia-Pacific Digital Respiratory Device Industry Recent Developments
- In November 2022, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. declared a new collaboration with HealthSnap, a leading full-service Virtual Care Management Platform for chronic disease management.
- In Feb 2022, Astra Zeneca Plc. and Honeywell came into a partnership to develop next-generation respiratory inhalers via the propellant HFO-1234ze, which has up to 99.9% less global warming potential (GWP) than propellants currently used in respiratory medicines.
Gain a Competitive Edge with Our Asia-Pacific Digital Respiratory Device Market Report
- Asia-Pacific Digital Respiratory Device Market report provides a detailed and thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics and make informed decisions.
- This report also highlights current market trends and future projections, allowing businesses to identify emerging opportunities and potential challenges. By understanding market forecasts, companies can align their strategies and stay ahead of the competition.
- Asia-Pacific Digital Respiratory Device Market report aids in assessing and mitigating risks associated with entering or operating in the market.
- The report would help in understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks and optimize their operations.
Frequently Asked Questions
Asia-Pacific Digital Respiratory Device Market Research Report (2023-2028) - Table of Contents
- Introduction
- Product Definition
- Research Process
- Glossary
- Market Segmentation
- Executive Summary
- Expert Verbatim- Interview Excerpts of Industry Experts
- Asia-Pacific Digital Respiratory Device Market Outlook, 2018-2028F
- Market Size & Analysis
- By Units Sold
- By Revenues
- Market Share & Analysis
- By Device Type
- Therapeutic Devices
- CPAP Devices
- BI-PAP Devices
- Humidifiers
- Nebulizers
- Ventilators
- Inhalers
- Oxygen Concentrates
- Resuscitators
- Diagnostics Monitoring Devices
- Spirometers
- Pulse Oximeters
- Consumables and Accessories
- Respiratory Therapy Wearable Medical Device
- Watch and Wristband
- Disposables
- Nasal Cannulas
- Filters
- Breathing Circuits
- Therapeutic Devices
- By End-User
- Homecare
- Hospitals and Clinics
- Ambulatory Care Centers
- By Application
- Chronic Obstructive Pulmonary Disease
- Sleep Apnea
- Asthma
- Infectious Disease
- By Country
- China
- India
- Japan
- Australia
- New Zealand
- South Korea
- Rest of Asia-Pacific
- By Company
- Revenue Shares
- Strategic Factorial Indexing
- Competitor Placement in MarkNtel Quadrant
- By Device Type
- Market Size & Analysis
- Asia Pacific Digital Respiratory Medical Device Market Outlook, 2018-2028F
- Market Size & Analysis
- By Units Sold
- By Revenue
- Market Share & Analysis
- By Product Type
- By End-User
- By Application
- China Digital Respiratory Medical Device Market Outlook, 2018-2028F
- Market Size & Analysis
- By Units Sold
- By Revenues
- Market Share & Analysis
- By Product
- By End-User
- By Application
- Market Size & Analysis
- India Digital Respiratory Medical Device Market Outlook, 2018-2028F
- Market Size & Analysis
- By Units Sold
- By Revenues
- Market Share & Analysis
- By Product
- By End-User
- By Application
- Market Size & Analysis
- Japan Digital Respiratory Medical Device Market Outlook, 2018-2028F
- Market Size & Analysis
- By Units Sold
- By Revenues
- Market Share & Analysis
- By Product
- By End-User
- By Application
- Market Size & Analysis
- Australia Digital Respiratory Medical Device Market Outlook, 2018-2028F
- Market Size & Analysis
- By Units Sold
- By Revenues
- Market Share & Analysis
- By Product
- By End-User
- By Application
- Market Size & Analysis
- New Zealand Digital Respiratory Medical Device Market Outlook, 2018-2028F
- Market Size & Analysis
- By Units Sold
- By Revenues
- Market Share & Analysis
- By Product
- By End-User
- By Application
- Market Size & Analysis
- South Korea Digital Respiratory Medical Device Market Outlook, 2018-2028F
- Market Size & Analysis
- By Units Sold
- By Revenue
- Market Share & Analysis
- By Product
- By End-User
- By Application
- Market Size & Analysis
- Rest of Asia-Pacific Digital Respiratory Medical Device Market Outlook, 2018-2028F
- Market Size & Analysis
- By Units Sold
- By Revenues
- Market Share & Analysis
- By Product
- By End-User
- By Application
- Market Size & Analysis
- Market Size & Analysis
- Asia-Pacific Digital Respiratory Device Dynamics
- Drivers
- Challenges
- Impact Analysis
- Asia-Pacific Digital Respiratory Device Regulations, Product Standards
- Asia-Pacific Digital Respiratory Device Value Chain Analysis
- Asia-Pacific Digital Respiratory Device Intellectual Property Rights Analysis
- Asia-Pacific Digital Respiratory Device Hotspots & Opportunities
- Competition Outlook
- Competitor Wise Growth Strategies
- Product Portfolio
- Brand Specialization
- Target Markets
- Research & Development
- Strategic Alliances & Initiatives
- Company Profiles
- Philips
- 3M Healthcare
- Astra Zenca Plc.
- Novartis AG
- GE Healthcare
- Masimo Corporation
- Cipla Ltd.
- Resmed Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Acorda Therapeutics
- Competitor Wise Growth Strategies
- Disclaimer